Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Arnd Nusch"'
Autor:
Patrick Neven, Xavier Pivot, Antonia Ridolfi, Brad Lanoue, J. Thaddeus Beck, Guy Jerusalem, Arnd Nusch, Francisco J. Esteva, Giulia Bianchi, David Chandiwana, Miguel Martin, Karen Rodriguez Lorenc, Peter A. Fasching, Arlene Chan, Yingbo Wang, Michele De Laurentiis
Publikováno v:
The Breast : Official Journal of the European Society of Mastology
Breast, Vol 54, Iss, Pp 148-154 (2020)
Breast, Vol 54, Iss, Pp 148-154 (2020)
Purpose In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and o
Autor:
Stephanie Dille, Richard A. Hansen, Johanna Harde, Karin Potthoff, Oliver Stötzer, Norbert Marschner, Ulrike Söling, Arnd Nusch
Publikováno v:
Clinical Breast Cancer. 20:e315-e326
Background There are only scarce data on treatment of elderly patients with nab-paclitaxel for metastatic breast cancer, especially from the real-world setting. Here we present data from the noninterventional study NABUCCO with special focus on taxan
Autor:
Mischa Moeller, Matthias Gunzer, Lea Bornemann, Karl-Heinz Jöckel, Lennart Martens, Noreen Pundt, Laura Witjes, Benedikt W. Pelzer, Katja Kruithoff, Christina Kohn, Arnd Nusch, Clara Bessen, Olga Just, Ulrich Germing, Rainer Haas, Saskia Schmitz, Christophe Ampe, Marleen Van Troys, Marc Schuster, Charlyn Sobczak, Andrea Kündgen
Publikováno v:
The Journal of Immunology. 201:3546-3557
Autonomous migration is a central characteristic of immune cells, and changes in this function have been correlated to the progression and severity of diseases. Hence, the identification of pathologically altered leukocyte migration patterns might be
Autor:
Sina Grebhardt, Arnd Nusch, Richard A. Hansen, Ulrike Söling, Johanna Harde, Karin Potthoff, Norbert Marschner, Christoph Salat
Publikováno v:
Clinical Breast Cancer. 18:e1323-e1337
One of the most effective chemotherapies for metastatic breast cancer (MBC) is nab-paclitaxel (nab-P), which is approved for treatment of MBC after failure of first-line therapy and when anthracyclines are not indicated. Randomized clinical trials ha
Autor:
Xavier Pivot, Michelle Miller, Seock-Ah Im, Francisco J. Esteva, Yingbo Wang, Miguel Martin, Arnd Nusch, Luis de la Cruz-Merino, Karen Rodriguez Lorenc, Patrick Neven, Dennis J. Slamon, K. Petrakova, Peter A. Fasching, J. Thaddeus Beck, Stephen Chia, Michelino De Laurentiis, Gena Vidam, Guy Jerusalem, Giulia Val Bianchi, Gabe S. Sonke, Tetiana Taran
Publikováno v:
Journal of Clinical Oncology. 36:2465-2472
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer who were treatment naïve or had received up to one line of pri
Autor:
Ulla von Verschuer, Lothar Müller, Michael Staehler, Martina Jänicke, Norbert Marschner, Arnd Nusch, Susanne Tech, Lisa Kruggel, Peter J. Goebell, Annette Sauer, Michael Scheffler
Publikováno v:
Clinical genitourinary cancer. 16(6)
Introduction Because the treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved dramatically over the past decade, data on patients' treatment and outcomes in routine practice, so called “real-world data,” are important to com
Autor:
Stefania Gori, Magdolna Dank, Lajos Hornyak, Sergio Santillana, Michelle DeSilvio, Ramona F. Swaby, Vladimir Semiglazov, Roma Parikh, Sara Margolin, Alessandra Fabi, Xavier Pivot, Ewa Chmielowska, Bogdan Żurawski, Rozenn Allerton, P. Bidoli, Fareha Nagi, Boguslawa Karaszewska, Alexey Manikhas, Eva Ciruelos, Arnd Nusch, Stephen Chan
Publikováno v:
Journal of Clinical Oncology. 33:1564-1573
Purpose CEREBEL compared the incidence of CNS metastases as first site of relapse in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer receiving lapatinib-capecitabine or trastuzumab-capecitabine. Patients and
Autor:
Wolfgang Knauf, Wolfgang Abenhardt, Ali Aldaoud, Arnd Nusch, Renate Grugel, Michaela Münz, Holger Hartmann, Norbert Marschner, null on behalf of the TLN Study Group
Publikováno v:
Oncology Research and Treatment. 37:635-644
SummaryBackground: Various treatment options exist for patients with multiple myeloma (MM). Clinical registries provide insight into routine treatment and identify changes in treatment over time. Patients and Methods: The Tumour Registry Lymphatic Ne
Autor:
Anne Favret, Kimberly L. Blackwell, Samit Hirawat, Erik Jakobsen, Carlos L. Arteaga, Emilio Alba, Shani Paluch-Shimon, Pierfranco Conte, Salomon M. Stemmer, Mario Campone, A. Chan, Lowell L. Hart, Thomas Bachelot, Fengjuan Xuan, David Cameron, Sunil Verma, Sibel Blau, Denise A. Yardley, Gabe S. Sonke, Farida Souami, Gabriel N. Hortobagyi, Katarína Petráková, Norbert Marschner, Wolfgang Janni, Fabrice Andre, Cristian Villanueva, Arnd Nusch, Eric P. Winer, Olga Burdaeva, Yoon Sim Yap, Joyce O'Shaughnessy, C. Germa, Michelle Miller, Erik Wist, Eva-Maria Grischke, Ling-Ming Tseng, Howard A. Burris
Publikováno v:
Hortobagyi, G N, Stemmer, S M, Burris, H A, Yap, Y-S, Sonke, G S, Paluch-Shimon, S, Campone, M, Blackwell, K L, André, F, Winer, E P, Janni, W, Verma, S, Conte, P, Arteaga, C L, Cameron, D A, Petrakova, K, Hart, L L, Villanueva, C, Chan, A, Jakobsen, E, Nusch, A, Burdaeva, O, Grischke, E-M, Alba, E, Wist, E, Marschner, N, Favret, A M, Yardley, D, Bachelot, T, Tseng, L-M, Blau, S, Xuan, F, Souami, F, Miller, M, Germa, C, Hirawat, S & O’Shaughnessy, J 2016, ' Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer ', New England Journal of Medicine, vol. 375, no. 18, pp. 1738-1748 . https://doi.org/10.1056/NEJMoa1609709
BACKGROUND: The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) and negative for human epidermal growth f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d8dab1e35ee3ea5009a3a02e3727218
https://hdl.handle.net/10668/10515
https://hdl.handle.net/10668/10515
Autor:
Martin Dreyling, Arnd Nusch, Guenter Fingerle-Rowson, Sebastian Fetscher, Lenka Kellermann, Peter Kornek, Christian Schmidt, Christian Görg, T. Kegel, Wolfgang Hiddemann
Publikováno v:
Clinical lymphoma, myelomaleukemia. 11(2)
Background In advanced-stage indolent lymphoma, therapeutic approaches may vary from watch and wait, antibody monotherapy, immunochemotherapy, or dose-intensified consolidation up to allogeneic strategies. In this nationwide survey, representative he